Pragmatic Trial of Psilocybin Therapy in Palliative Care

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 19, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Demoralization
Interventions
DRUG

Psilocybin

Psilocybin, \[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate.

DRUG

Ketamine

ketamine hydrochloride injection, for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic and has a molecular formula of C13H16ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is (±)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.

Trial Locations (3)

20850

RECRUITING

Sunstone Therapies, Rockville

90502

RECRUITING

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance

94518

RECRUITING

University of San Francisco, San Francisco

All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

lead

Charles S. Grob, M.D.

OTHER